ARS Pharmaceuticals, Inc. — Director's Dealing 2025

Jun 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-06-18

Reporting Person: Karas Eric (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-18	Common Stock	M	15000	$1.5	Acquired	22696	Direct
2025-06-18	Common Stock	S	15000	$16	Disposed	7696	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-18	Stock Option (Right to Buy)	$1.50	M	15000	Disposed	2032-05-23	Common Stock (15000)	Direct

Footnotes

F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

F2: Immediately exercisable.